Apolipoprotein A-I mimetic peptides
Authors:
- Andrea E BochemABAndrea E Bochem
- John Jp KasteleinJKJohn Jp Kastelein
- 1 December 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 21 (6) , 481-486
Abstract
To review published data related to the potential applicability of apolipoprotein A-I mimetic peptides. Despite a wealth of information on HDL-C levels and risk for cardiovascular disease (CVD), little evidence is present to suggest that raising HDL-C levels per se will result in CVD risk reduction. Rather, increasing HDL functionality might be a more successful strategy to reverse the process of atherosclerosis. In as such, apoA-I mimetic peptides, either in single or tandem formulation, hold great promise. Evidence gathered over the last years has provided insight in the extent to which mimetics influence several cardio metabolic pathways. ApoA-I mimetics have shown to have anti-inflammatory, antioxidant, and antiatherogenic effects. Direct comparisons between different mimetics have provided insight in factors influencing the differential beneficial consequences of these peptides. Data derived from recent studies suggest that mimetics might gain their position as a therapeutic intervention in the treatment of septicaemia, transplantation rejection, diabetes and auto-immune diseases. This review provides a summary of the current literature on the potential application of apoA-I mimetics as therapeutic agents. There is increasing evidence that these mimetics should be considered as a promising supplement to current strategies. Results from human studies addressing the in-vivo effects of the different apoA-I mimetics are eagerly awaited.Keywords
This publication has 58 references indexed in Scilit:
- The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic ratsJournal of Lipid Research, 2010
- The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Journal of Lipid Research, 2010
- Structure/Function Relationships of Apolipoprotein A-I Mimetic PeptidesCirculation Research, 2010
- A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in miceJournal of Lipid Research, 2010
- Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosisArthritis Research & Therapy, 2010
- The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In VitroArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- L-4F Alters Hyperlipidemic (But Not Healthy) Mouse Plasma to Reduce Platelet AggregationArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Dysfunctional HDL as a Diagnostic and Therapeutic TargetArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patientsJournal of Lipid Research, 2008
- Beyond High-Density Lipoprotein Cholesterol LevelsJACC, 2008